证券日报网讯 新和成（002001）9月30日在互动平台回答投资者提问时表示，公司生产的维生素A和维 生素E产品涵盖了饲料级、食品级和医药级等多个级别，以满足不同领域的需求。在高端维生素A和维 生素E方面，公司拥有相关产品，并且在全球范围内具有显著的竞争力。公司已获得美国、欧洲、日本 等主要市场的市场准入资格，产品在这些市场得到了广泛认可。 ...

公 司 研 究 / 基 础 化 工 / 证 券 研 究 报 告 新和成（002001）财报点评 Q2 维生素价格环比下降，蛋氨酸项目 投入试运行 2025 年 09 月 30 日 【投资要点】 挖掘价值 投资成长 增持（维持） 东方财富证券研究所 证券分析师：张志扬 证书编号：S1160524100006 证券分析师：梅宇鑫 证书编号：S1160525020002 相对指数表现 -20% -12% -4% 4% 12% 20% 2024/9 2025/3 2025/9 新和成 沪深300 | 基本数据 | | | --- | --- | | 总市值（百万元） | 72,993.76 | | 流通市值（百万元） | 72,125.47 | | 52 周最高/最低（元） | 25.19/19.55 | | 52 周最高/最低（PE） | 13.19/10.24 | | 52 周最高/最低（PB） | 2.64/2.05 | | 52 周涨幅（%） | 21.48 | | 52 周换手率（%） | 51.74 | 注：数据更新日期截止 2025 年 09 月 29 日 相关研究 《公司产品量价齐升，2024 年保持 ...

Financial Performance - In the first half of 2025, the company achieved a revenue of 11.101 billion yuan, a year-on-year increase of 12.76% [1] - The net profit attributable to shareholders was 3.603 billion yuan, reflecting a significant year-on-year growth of 63.46% [1] - For Q2 2025, the company reported a revenue of 5.661 billion yuan, up 5.89% year-on-year and 4.07% quarter-on-quarter [1] - The net profit for Q2 2025 was 1.723 billion yuan, showing a year-on-year increase of 29.12% but a quarter-on-quarter decrease of 8.32% [1] Product Development and Market Expansion - The company is actively promoting new products such as HA series and tryptophan while maintaining its market advantage in existing products [2] - The liquid methionine project in partnership with Sinopec is in trial production, and the Tianjin nylon new materials project has completed compliance approvals [2] - Other technical upgrades and management improvement projects are progressing steadily, with new project planning being conducted in an orderly manner [2] Pricing and Market Trends - Prices for major products showed a mixed trend, with some prices decreasing quarter-on-quarter while others increased year-on-year [3] - The average prices for vitamins A, E, D3, C, and methionine in Q2 2025 were 73.67, 104.38, 237.15, 21.04, and 22.27 yuan/kg, respectively [3] - The nutrition products segment generated a revenue of 7.200 billion yuan in H1 2025, a year-on-year increase of 7.78%, with a gross margin of 47.79%, up 11.93 percentage points year-on-year [3] Future Outlook - The company is a leading player in the domestic market for vitamins A, E, and methionine, with the methionine project expected to gradually contribute to profits [4] - Revenue forecasts for 2025-2027 are projected at 23.938 billion, 26.136 billion, and 28.785 billion yuan, with net profits of 6.741 billion, 7.139 billion, and 7.641 billion yuan, respectively [4] - The price-to-earnings ratios for 2025-2027 are estimated to be 10.83, 10.23, and 9.55 times, maintaining a "buy" rating [4]

Summary of the Conference Call Company and Industry Overview - The conference call focuses on the vitamin industry, particularly the role of vitamins in animal nutrition and the performance of the company Xinhecheng in this sector [2][12][18]. Key Points and Arguments Vitamin Demand in Animal Nutrition - Industrialized farming relies heavily on vitamin additives, with feed demand accounting for approximately 60%, and certain vitamins like A and D3 reaching up to 80% [2][5]. - In 2022, pig and poultry feed constituted 86% of China's total feed demand, with pig feed around 45% and poultry feed at 41% [9]. - The profitability of farming significantly influences vitamin demand, with farmers reducing vitamin usage during low-profit periods [9][10]. Market Dynamics and Trends - The vitamin industry has evolved from monopolies by companies like Merck and Roche to increased competition from Japanese firms and Chinese companies like Xinhecheng and Zhejiang Medicine [2][12]. - The global vitamin market currently faces an oversupply, leading companies to halt production to maintain prices [2][13]. - Seasonal demand for animal nutrition supplements peaks in the fourth quarter due to pre-holiday fattening, while summer demand is relatively low [2][14]. Price Fluctuations and Influencing Factors - Vitamin prices are influenced by environmental policies, raw material supply constraints, and unforeseen events [14][15]. - Historical trends show that demand typically sets the price baseline, while supply determines the price ceiling [15]. Xinhecheng's Strategic Positioning - Xinhecheng is diversifying its portfolio beyond vitamins, focusing on amino acids, flavoring agents, and new materials, which have shown strong growth [4][18]. - The company has established a competitive edge in the flavoring market, achieving a gross margin exceeding 50% [19]. - Xinhecheng's new materials business has also seen rapid growth, with products like PPS and PPA reaching global leading levels [20]. Financial Performance and Future Outlook - In 2024, vitamin E prices were at historical highs, significantly contributing to the company's profits, but overall profit impact from vitamin price fluctuations is limited [21]. - The company is expected to continue providing good shareholder returns, including special dividends in profitable years [24]. Market Conditions for Methionine - The market for methionine is stable, with concerns about price impacts from new production capacity being mitigated by steady demand [22][23]. Additional Important Insights - The vitamin market's supply-demand relationship has historically influenced pricing, with significant fluctuations observed during periods of high profitability in the livestock sector [15][16]. - Xinhecheng's long-term growth potential and strong financial metrics make it an attractive option for long-term investors [24].

Market Performance - The new materials sector experienced a decline this week, with the new materials index falling by 0.31%, underperforming the ChiNext index by 2.67% [1][2] - Over the past five trading days, the synthetic biology index decreased by 0.51%, semiconductor materials dropped by 4.74%, and specialty chemicals fell by 1.54%. In contrast, biodegradable plastics saw a slight increase of 0.02%, while industrial gases declined by 1.20%. Battery chemical products surged by 13.36% [1][2] Price Tracking - Amino acids prices showed the following changes: valine at 12,750 CNY/ton (-1.92%), arginine at 22,900 CNY/ton (-1.08%), tryptophan at 39,500 CNY/ton (-4.82%), and methionine at 22,050 CNY/ton (-0.68%) [3] - Prices for biodegradable materials remained stable: PLA (FY201 injection grade) at 17,800 CNY/ton, PLA (REVODE201 blow film grade) at 17,200 CNY/ton, PBS at 17,800 CNY/ton, and PBAT at 9,850 CNY/ton [3] - Vitamin prices were as follows: Vitamin A at 64,000 CNY/ton (unchanged), Vitamin E at 64,500 CNY/ton (-1.53%), Vitamin D3 at 227,500 CNY/ton (unchanged), calcium pantothenate at 40,500 CNY/ton (unchanged), and inositol at 26,000 CNY/ton (unchanged) [3] - Industrial gases and wet electronic chemicals prices remained unchanged: UPSSS grade hydrofluoric acid at 11,000 CNY/ton and EL grade hydrofluoric acid at 5,600 CNY/ton [3] - In the plastics and fibers category, carbon fiber remained at 83,750 CNY/ton (unchanged), polyester industrial yarn at 8,500 CNY/ton (-2.30%), and aramid at 102,700 CNY/ton (+17.62%). The export average price for polyester tire cord fabric in July was 16,353 CNY/ton (-0.61%) [3] Investment Opportunities - The DAC project has been included in Shanghai's 2025 key technology research and development plan, highlighting opportunities in domestic DAC adsorbents and equipment [4] - The recognition and strong support from various government levels for DAC technology mark a significant milestone in addressing climate change and promoting green energy development [5] - The establishment of a thousand-ton demonstration project will provide valuable engineering data and operational experience for future commercial projects, potentially enhancing DAC product performance and reducing capture costs [5] - Companies to watch for key adsorbent materials and related equipment include Blue Sky Technology, Jianlong Micro-Nano, Xizhuang Co., China Energy Construction, GCL-Poly, and United Water [5]

Investment Rating - The report maintains a positive outlook on the basic chemical industry, suggesting that leading companies with significant scale and cost advantages will benefit from economic recovery and demand resurgence [4][8]. Core Insights - The report highlights the recovery of the TDI production facility by Mitsui and the successful commissioning of a new ethylene plant by Jilin Petrochemical, indicating positive developments in the industry [3][4]. - It emphasizes the strong competitive position of domestic tire manufacturers and suggests that rare growth stocks in this sector are worth attention [4]. - The report notes a potential recovery in consumer electronics, recommending upstream material companies as beneficiaries of this trend [4]. - It identifies several resilient cyclical industries, such as phosphate and fluorine chemicals, which are expected to see improved market conditions due to supply constraints and rising demand [5][8]. Summary by Sections Market Performance - The Shanghai Composite Index fell by 1.18%, while the ChiNext Index rose by 2.35%. The CITIC Basic Chemical Index increased by 0.15%, and the Shenwan Chemical Index decreased by 1.36% [14][17]. - The top-performing sub-industries included organic silicon (3.59%), modified plastics (2.46%), and tires (2.22%), while the worst performers were other plastic products (-4.72%) and compound fertilizers (-3.04%) [17][18]. Industry Dynamics - Mitsui's TDI plant is set to resume production after a chlorine leak incident, with expectations of stable product supply [3]. - Jilin Petrochemical's new ethylene plant has successfully started operations, increasing its total ethylene capacity to 1.9 million tons per year [3]. Investment Themes - **Tire Sector**: Domestic tire companies are noted for their strong competitive edge, with recommendations to focus on companies like Sailun Tire and Linglong Tire [4]. - **Consumer Electronics**: A gradual recovery is anticipated, with upstream material companies expected to benefit from increased demand in the panel supply chain [4]. - **Cyclical Industries**: Phosphate and fluorine chemical sectors are highlighted for their resilience, with recommendations for companies like Yuntianhua and Juhua [5][8]. - **Leading Companies**: The report suggests that leading companies in the chemical sector, such as Wanhua Chemical and Hualu Hengsheng, will benefit from economic recovery and demand resurgence [8].

Core Viewpoint - The company emphasizes its commitment to innovation-driven development and market competition, focusing on fine chemicals and achieving domestic production of key products like Vitamin E and A [2] Group 1: Company Strategy - The company relies on two core platforms: chemical and biological, to develop functional chemicals in nutrition, flavors, new materials, and raw pharmaceuticals [2] - The company adheres to the values of "innovation, people-oriented, and competitive success," and follows a development approach of "integration, serialization, and collaboration" [2] Group 2: Product Development - The company has successfully achieved the domestic production of various products, including Vitamin E, Vitamin A, PPS, and methionine, contributing to industrial transformation and upgrading [2] Group 3: Future Focus - The company plans to enhance its technological innovation, global layout, and digital intelligence to strengthen management and improve overall competitiveness [2]

Investment Rating - The investment rating for the company is "Buy" with a target of outperforming the industry index by more than 15% over the next six months [5][19]. Core Views - The company's profitability has significantly increased year-on-year, with a notable rise in net profit driven by the life nutrition products segment [2][11]. - The vitamin industry is expected to continue its upward trend, benefiting from increased market demand and price fluctuations [4][11]. - The company is implementing cost reduction and efficiency improvement measures across its two main segments to enhance competitiveness and support future growth [10][11]. Financial Performance Summary - For the first half of 2025, the company reported a revenue of 4.323 billion, a decrease of 1.87% year-on-year, while net profit increased by 113.52% to 673 million [1][2]. - The overall gross margin for the first half of 2025 was 39.82%, an increase of 4.43 percentage points compared to the same period in 2024 [2]. - The life nutrition products segment generated a revenue of 2.034 billion, a slight increase of 0.58% year-on-year, with a gross margin of 54.95%, up 15.41 percentage points [4][10]. Cash Flow and Financial Ratios - The net cash flow from operating activities for the first half of 2025 was 798 million, a significant increase of 281.20% year-on-year [3]. - The company’s cash and cash equivalents at the end of the period stood at 2.709 billion, an increase of 84.43% year-on-year [3]. - The projected earnings per share (EPS) for 2025 is 1.16, with corresponding P/E ratios of 13.5, 9.9, and 9.2 for the years 2025, 2026, and 2027 respectively [11].

Core Viewpoint - Wanhua Chemical (600309) is recognized as a global leader in the chemical industry, with a strong focus on MDI and TDI products, and is expected to benefit from improving market conditions and strategic expansions [2][3]. Investment Highlights - Wanhua Chemical is a leading global chemical company with a diversified business structure, focusing on MDI and TDI as core products while expanding into petrochemicals, fine chemicals, and new materials [2]. - The MDI business is experiencing improved supply-demand dynamics, with the company's market share projected to increase from 22% in 2020 to 32% by 2024, supported by limited new capacity in the industry [2]. - The company plans to expand its MDI capacity by 700,000 tons/year, with new production expected to come online in 2026, further solidifying its market position [2]. - The TDI market is also characterized by oligopoly, with prices rising due to supply disruptions. Wanhua Chemical has a TDI capacity of 1.44 million tons/year and is expected to benefit from price increases [3]. - The petrochemical sector is anticipated to recover as industry profitability improves, with Wanhua Chemical's projects expected to enhance its competitive edge [3]. - The fine chemicals and new materials segment is seeing growth, with several new products set to launch between 2024 and 2025, contributing to revenue diversification [4]. - Revenue forecasts for Wanhua Chemical are projected at 185.6 billion, 193.9 billion, and 202.7 billion yuan for 2025, 2026, and 2027, respectively, with net profits expected to reach 13.5 billion, 16.5 billion, and 19 billion yuan [4]. - The company has received a "buy" rating from analysts, reflecting confidence in its leading position in the polyurethane industry and the potential for revenue growth from new projects [4][7].

Group 1 - The core viewpoint of the articles highlights the strong performance of Andisu in the first half of 2025, with a 17% year-on-year increase in revenue to 8.51 billion yuan and a 22% increase in net profit attributable to shareholders to 740 million yuan [1][2] - The sales of methionine business grew by 16% year-on-year, driven by the increasing market penetration of liquid methionine, despite challenges from regional price declines and rising raw material costs [1][2] - The special products business saw a 9% increase in revenue to 2.04 billion yuan and a 7% increase in gross profit to 830 million yuan, attributed to strong sales growth in ruminant products and a rebound in aquatic product sales [1][2] Group 2 - The "China Integration Strategy" has successfully driven strong sales growth in the first half of 2025, with double-digit growth in liquid methionine and significant orders in the aquatic market [2] - Andisu announced a refinancing plan to raise no more than 3 billion yuan to support investment projects, which has been approved by the Shanghai Stock Exchange and is currently in the registration process with the China Securities Regulatory Commission [2] - The company implemented a mid-term and annual dividend plan with an overall payout ratio of 40.08%, distributing 161 million yuan as mid-term dividends and 322 million yuan as annual dividends to shareholders [2]